Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study

Javier Garau, Francesco Blasi, Jesús Medina, Kyle McBride, Helmut Ostermann

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or Community-Acquired Pneumonia in the Hospital Setting) was a retrospective observational study of cSSTI patients in real-life settings in European hospitals. In this analysis, we review characteristics and outcomes of patients with an early response (≤72 hours) compared with those without an early response to treatment. We also compare the results according to two differing definitions of early response, one of which (Definition 1) requires resolution of fever within 72 hours, in line with previous US FDA guidelines.

METHODS: Patients were adults hospitalized with cSSTIs 2010-2011 and requiring treatment with intravenous antibiotics. Clinical management, clinical outcomes and healthcare resource use were assessed using a descriptive analysis approach.

RESULTS: The analysis set included 600 patients, of which 363 showed early response with Definition 1 and 417 with Definition 2. Initial treatment modification was frequent, and highest in patients without early response (48.1% with Definition 1). Patients without early response were more likely to have diabetes than those with early response (31.6% vs. 22.9%, respectively) and to suffer from more severe disease (e.g. skin necrosis: 14.8% and 7.7%, respectively), to be infected with difficult-to-treat microorganisms and to have recurrent infections. Furthermore, patients without early response had a higher rate of adverse clinical outcomes (e.g. septic shock) and higher use of healthcare resources. The results obtained with the two definitions for early response were largely similar.

CONCLUSIONS: This study highlights the significance of early evaluation of patients in hospitals, in potentially preventing prolonged use of inappropriate or ineffective antibacterial therapy.

TRIAL REGISTRATION: NCT01293435 .

Original languageEnglish
Pages (from-to)78
Number of pages1
JournalBMC Infectious Diseases
Volume15
DOIs
Publication statusPublished - 2015

Fingerprint

Soft Tissue Infections
Anti-Bacterial Agents
Skin
Therapeutics
Retrospective Studies
Delivery of Health Care
Septic Shock
Skin Diseases
Observational Studies
Pneumonia
Fever
Necrosis
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections : analysis of the REACH study. / Garau, Javier; Blasi, Francesco; Medina, Jesús; McBride, Kyle; Ostermann, Helmut.

In: BMC Infectious Diseases, Vol. 15, 2015, p. 78.

Research output: Contribution to journalArticle

@article{164ceb8a4ef14f05a19e6d8605ee2653,
title = "Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study",
abstract = "BACKGROUND: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or Community-Acquired Pneumonia in the Hospital Setting) was a retrospective observational study of cSSTI patients in real-life settings in European hospitals. In this analysis, we review characteristics and outcomes of patients with an early response (≤72 hours) compared with those without an early response to treatment. We also compare the results according to two differing definitions of early response, one of which (Definition 1) requires resolution of fever within 72 hours, in line with previous US FDA guidelines.METHODS: Patients were adults hospitalized with cSSTIs 2010-2011 and requiring treatment with intravenous antibiotics. Clinical management, clinical outcomes and healthcare resource use were assessed using a descriptive analysis approach.RESULTS: The analysis set included 600 patients, of which 363 showed early response with Definition 1 and 417 with Definition 2. Initial treatment modification was frequent, and highest in patients without early response (48.1{\%} with Definition 1). Patients without early response were more likely to have diabetes than those with early response (31.6{\%} vs. 22.9{\%}, respectively) and to suffer from more severe disease (e.g. skin necrosis: 14.8{\%} and 7.7{\%}, respectively), to be infected with difficult-to-treat microorganisms and to have recurrent infections. Furthermore, patients without early response had a higher rate of adverse clinical outcomes (e.g. septic shock) and higher use of healthcare resources. The results obtained with the two definitions for early response were largely similar.CONCLUSIONS: This study highlights the significance of early evaluation of patients in hospitals, in potentially preventing prolonged use of inappropriate or ineffective antibacterial therapy.TRIAL REGISTRATION: NCT01293435 .",
author = "Javier Garau and Francesco Blasi and Jes{\'u}s Medina and Kyle McBride and Helmut Ostermann",
year = "2015",
doi = "10.1186/s12879-015-0822-2",
language = "English",
volume = "15",
pages = "78",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections

T2 - analysis of the REACH study

AU - Garau, Javier

AU - Blasi, Francesco

AU - Medina, Jesús

AU - McBride, Kyle

AU - Ostermann, Helmut

PY - 2015

Y1 - 2015

N2 - BACKGROUND: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or Community-Acquired Pneumonia in the Hospital Setting) was a retrospective observational study of cSSTI patients in real-life settings in European hospitals. In this analysis, we review characteristics and outcomes of patients with an early response (≤72 hours) compared with those without an early response to treatment. We also compare the results according to two differing definitions of early response, one of which (Definition 1) requires resolution of fever within 72 hours, in line with previous US FDA guidelines.METHODS: Patients were adults hospitalized with cSSTIs 2010-2011 and requiring treatment with intravenous antibiotics. Clinical management, clinical outcomes and healthcare resource use were assessed using a descriptive analysis approach.RESULTS: The analysis set included 600 patients, of which 363 showed early response with Definition 1 and 417 with Definition 2. Initial treatment modification was frequent, and highest in patients without early response (48.1% with Definition 1). Patients without early response were more likely to have diabetes than those with early response (31.6% vs. 22.9%, respectively) and to suffer from more severe disease (e.g. skin necrosis: 14.8% and 7.7%, respectively), to be infected with difficult-to-treat microorganisms and to have recurrent infections. Furthermore, patients without early response had a higher rate of adverse clinical outcomes (e.g. septic shock) and higher use of healthcare resources. The results obtained with the two definitions for early response were largely similar.CONCLUSIONS: This study highlights the significance of early evaluation of patients in hospitals, in potentially preventing prolonged use of inappropriate or ineffective antibacterial therapy.TRIAL REGISTRATION: NCT01293435 .

AB - BACKGROUND: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or Community-Acquired Pneumonia in the Hospital Setting) was a retrospective observational study of cSSTI patients in real-life settings in European hospitals. In this analysis, we review characteristics and outcomes of patients with an early response (≤72 hours) compared with those without an early response to treatment. We also compare the results according to two differing definitions of early response, one of which (Definition 1) requires resolution of fever within 72 hours, in line with previous US FDA guidelines.METHODS: Patients were adults hospitalized with cSSTIs 2010-2011 and requiring treatment with intravenous antibiotics. Clinical management, clinical outcomes and healthcare resource use were assessed using a descriptive analysis approach.RESULTS: The analysis set included 600 patients, of which 363 showed early response with Definition 1 and 417 with Definition 2. Initial treatment modification was frequent, and highest in patients without early response (48.1% with Definition 1). Patients without early response were more likely to have diabetes than those with early response (31.6% vs. 22.9%, respectively) and to suffer from more severe disease (e.g. skin necrosis: 14.8% and 7.7%, respectively), to be infected with difficult-to-treat microorganisms and to have recurrent infections. Furthermore, patients without early response had a higher rate of adverse clinical outcomes (e.g. septic shock) and higher use of healthcare resources. The results obtained with the two definitions for early response were largely similar.CONCLUSIONS: This study highlights the significance of early evaluation of patients in hospitals, in potentially preventing prolonged use of inappropriate or ineffective antibacterial therapy.TRIAL REGISTRATION: NCT01293435 .

UR - http://www.scopus.com/inward/record.url?scp=84964315163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964315163&partnerID=8YFLogxK

U2 - 10.1186/s12879-015-0822-2

DO - 10.1186/s12879-015-0822-2

M3 - Article

C2 - 25879713

VL - 15

SP - 78

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

ER -